← Eichor
Study identifier: NCT03458195 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Ileal Crohn's Disease and Post-operative Outcome: Prospective Cohort Study of the REMIND Group

Condition: Crohn Disease  ·  Sponsor: Saint-Louis Hospital, Paris, France

PhaseNA
Planned participants575
Who can joinAll sexes, 18 Years to 100 Years
Healthy volunteersNo

About this study

Crohn's disease (CD), a chronic inflammatory process in intestinal segments leads to tissue damage. More than two thirds of CD patients need intestinal resection. Symptomatic clinical recurrence occurs in 60% by 10 years. The principal factors affecting postoperative recurrence are active smoking, penetrating disease, perianal lesions history, prior intestinal resection, small bowel resection extent, and prophylaxis treatment absence. Ileocolonoscopy within one year of surgery can predict clinical recurrence risk. Different therapies are proposed after surgery, to prevent post-operative recurrence : Thiopurines, 6-mercaptopurine (positive for clinical and endoscopic postoperative recurrence prevention), Anti-tumour necrosis factor therapy (anti-TNF), the most effective therapy. Intestinal microbiota acts as a central factor in the CD pathogenesis, and fecal stream role is clearly shown. Various changes in luminal flora with a possible link to local inflammation was also demonstrated. Bacteria associated with postoperative recurrence could be more pathogenic as adherent invasive E coli (AIEC), which could be a pathogen in CD through several mechanisms including increased mucosal colonization, adherence, replication and induction of TNF secretion. Alternatively, postoperative CD recurrence could be linked to a protective commensal species lack, such as Faecalibacterium prausnitzii. Microscopic inflammation occurs as early as 8 days after anastomosis in the neoterminal ileum…

This description comes directly from the study's public registry record.

Talk to the study team

Matthieu ALLEZ, Pr  ·  +33(1) 42 49 95 75  ·  Matthieu.allez@aphp.fr

Philippe SEKSIK, Pr  ·  +33(1) 49 28 31 62  ·  Philippe.seksik@aphp.fr

Always discuss trial participation with your own doctor first.

Locations (17)

SART Tilman HospitalLiège, BelgiumRecruiting
Amiens HospitalAmiens, FranceRecruiting
Haut-levêque HospitalBordeaux, FranceActive Not Recruiting
Clermont-Ferrand HospitalClermont-Ferrand, FranceRecruiting
Beaujon HospitalClichy, FranceRecruiting
Henri Mondor HospitalCréteil, FranceRecruiting
Kremlin-Bicêtre HospitalLe Kremlin-Bicêtre, FranceRecruiting
Lille HospitalLille, FranceRecruiting
Hôpital Nord, CHU MarseilleMarseille, FranceRecruiting
Montpellier HospitalMontpellier, FranceRecruiting
Brabois HospitalNancy, FranceRecruiting
Nantes HospitalNantes, FranceRecruiting

+ 5 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03458195